Eric Honroth - 02 Nov 2026 Form 4 Insider Report for ANGIODYNAMICS INC (ANGO)

Reporting relationship: President and CEO, Director
Issuer ticker: ANGO
Reported as of: 02 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Nov 2026, 18:56:24 UTC
Source filing: View source filing
Reporting owner signature: /s/ Lawrence T. Weiss, as Attorney in Fact

Filing notes and source

Key filing fact

Eric Honroth filed Form 4 for ANGIODYNAMICS INC (ANGO) on 04 Nov 2026.

Key facts

This page summarizes Eric Honroth's Form 4 filing for ANGIODYNAMICS INC (ANGO).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Nov 2026, 18:56.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002162813 Primary reporting owner

Honroth Eric

Relationship: President and CEO, Director
Address: 14 PLAZA DRIVE, LATHAM
Signature: /s/ Lawrence T. Weiss, as Attorney in Fact
Signature date: 04 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANGO transaction

Common Stock

Award

Transaction value
Shares: +62,928
Change %
Price: $0.000000^*
Shares after: 62,928
Date: 02 Nov 2026
Ownership: Direct
Footnotes: F1

ANGO transaction

Common Stock

Award

Transaction value
Shares: +38,265
Change %: +61%
Price: $0.000000^*
Shares after: 101,193
Date: 02 Nov 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ANGO transaction Derivative

Performance Right

Award

Transaction value
Shares: +62,928
Change %
Price: $0.000000^*
Shares after: 62,928
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 62,928
Exercise price
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The acquisition of 62,928 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") represents 62,928 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments consistent with awards granted to other executive officers of the Company and beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued employment through each applicable vesting date.

Footnote F2

The acquisition of 38,265 shares of Common Stock represents 38,265 restricted stock units granted to replace equity compensation the Reporting Person forfeited at his prior employer, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in two equal annual installments, such that 50% of the restricted stock units will vest on each of November 2, 2027 and November 2, 2028, subject to the Reporting Person's continued employment through each vesting date.

Footnote F3

Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned, if at all, based on a combination of the Company's revenue, adjusted EBITDA, and total shareholder return ("TSR") relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement to the extent relative TSR over the three-year performance period exceeds the 75th percentile or is below the 25th percentile (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.